AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Last week, AbbVie said that it would record a charge of about $3.5 billion related to the drug. The company is looking to compete with Bristol Myers Squibb's (BMY.N), opens new tab Cobenfy ...